825 related articles for article (PubMed ID: 19747633)
1. Partially matched related hematopoietic stem cell transplantation without ex vivo T cell depletion compared with matched unrelated transplantation in adult patients with hematologic malignancies.
Wang Y; Chen F; Han Y; Fu ZZ; Tang XW; Miao M; Qiu HY; Jin ZM; Sun AN; Wu DP
Biol Blood Marrow Transplant; 2009 Oct; 15(10):1258-64. PubMed ID: 19747633
[TBL] [Abstract][Full Text] [Related]
2. Partially matched related donor transplantation can achieve outcomes comparable with unrelated donor transplantation for patients with hematologic malignancies.
Xiao-Jun H; Lan-Ping X; Kai-Yan L; Dai-Hong L; Yu W; Huan C; Yu-Hong C; Wei H; Jing-Zhi W; Yao C; Xiao-Hui Z; Hong-Xia S; Feng-Rong W; Fei-Fei T
Clin Cancer Res; 2009 Jul; 15(14):4777-83. PubMed ID: 19584148
[TBL] [Abstract][Full Text] [Related]
3. Similar survival following HLA-identical sibling transplantation for standard indication in children with haematologic malignancies: a single center comparison of mobilized peripheral blood stem cell with bone marrow transplantation.
Meisel R; Enczmann J; Balzer S; Bernbeck B; Kramm C; Schönberger S; Sinha K; Tröger A; Wernet P; Göbel U; Laws HJ; Dilloo D
Klin Padiatr; 2005; 217(3):135-41. PubMed ID: 15858704
[TBL] [Abstract][Full Text] [Related]
4. Comparable long-term survival after bone marrow versus peripheral blood progenitor cell transplantation from matched unrelated donors in children with hematologic malignancies.
Meisel R; Laws HJ; Balzer S; Bernbeck B; Kramm C; Schönberger S; Sinha K; Tröger A; Schmitz M; Fischer J; Göbel U; Enczmann J; Dilloo D
Biol Blood Marrow Transplant; 2007 Nov; 13(11):1338-45. PubMed ID: 17950920
[TBL] [Abstract][Full Text] [Related]
5. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC
Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
[TBL] [Abstract][Full Text] [Related]
6. Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies.
Valcárcel D; Martino R; Sureda A; Canals C; Altés A; Briones J; Sanz MA; Parody R; Constans M; Villela SL; Brunet S; Sierra J
Eur J Haematol; 2005 Feb; 74(2):144-51. PubMed ID: 15654906
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of transplantation with partial T-cell depletion of matched or mismatched unrelated or partially matched related donor bone marrow in children and adolescents with leukemias.
Bunin N; Aplenc R; Leahey A; Magira E; Grupp S; Pierson G; Monos D
Bone Marrow Transplant; 2005 Jan; 35(2):151-8. PubMed ID: 15531896
[TBL] [Abstract][Full Text] [Related]
8. Comparison of two doses of antithymocyte globulin in patients undergoing matched unrelated donor allogeneic stem cell transplantation.
Ayuk F; Diyachenko G; Zabelina T; Wolschke C; Fehse B; Bacher U; Erttmann R; Kröger N; Zander AR
Biol Blood Marrow Transplant; 2008 Aug; 14(8):913-9. PubMed ID: 18640575
[TBL] [Abstract][Full Text] [Related]
9. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.
Chen XH; Zhang C; Zhang X; Gao L; Gao L; Kong PY; Peng XG; Qi DG; Sun AH; Zeng DF; Liu H; Gong Y; Wang QY
Biol Blood Marrow Transplant; 2009 Feb; 15(2):266-73. PubMed ID: 19167687
[TBL] [Abstract][Full Text] [Related]
10. Does younger donor age affect the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies beneficially?
Mehta J; Gordon LI; Tallman MS; Winter JN; Evens AM; Frankfurt O; Williams SF; Grinblatt D; Kaminer L; Meagher R; Singhal S
Bone Marrow Transplant; 2006 Jul; 38(2):95-100. PubMed ID: 16751789
[TBL] [Abstract][Full Text] [Related]
11. [Effects and prognostic factors of HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia].
Tong XZ; Li J; Tan EX; Zhang GC; Wu XY; Peng AH; Zheng D; Zou WY; Hong WD; Luo SK
Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):545-8. PubMed ID: 17147125
[TBL] [Abstract][Full Text] [Related]
12. A novel approach to human leukocyte antigen-mismatched transplantation in patients with malignant hematological disease.
Huang XJ; Han W; Xu LP; Chen YH; Liu DH; Lu J; Chen H; Zhang YC; Jiang Q; Liu KY; Lu DP
Chin Med J (Engl); 2004 Dec; 117(12):1778-85. PubMed ID: 15603704
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
Kuruvilla J; Shepherd JD; Sutherland HJ; Nevill TJ; Nitta J; Le A; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Toze CL; Smith CA; Barnett MJ; Song KW
Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
[TBL] [Abstract][Full Text] [Related]
14. Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies.
Huang XJ; Liu DH; Liu KY; Xu LP; Chen H; Han W; Chen YH; Wang JZ; Gao ZY; Zhang YC; Jiang Q; Shi HX; Lu DP
Bone Marrow Transplant; 2006 Aug; 38(4):291-7. PubMed ID: 16883312
[TBL] [Abstract][Full Text] [Related]
15. [A comparison of clinical outcomes between unrelated donor and HLA-haploidentical donor hematopoietic stem cell transplantation].
Chen F; Wu DP; Sun AN; Ma X; Tang XW; Qiu HY; Miao M; Fu ZZ; Jin ZM; Wang Y; Wu XJ; Chen SN; He GS; Wang XL; Xue SL; Zhao Y; Chang WR
Zhonghua Xue Ye Xue Za Zhi; 2008 Feb; 29(2):83-6. PubMed ID: 18681306
[TBL] [Abstract][Full Text] [Related]
16. Allogeneic transplantation from HLA-matched sibling or partially HLA-mismatched related donors for primary refractory acute leukemia.
Singhal S; Powles R; Henslee-Downey PJ; Chiang KY; Treleaven J; Godder K; Kulkarni S; van Rhee F; Sirohi B; Pinkerton CR; Meller S; Mehta J
Bone Marrow Transplant; 2002 Feb; 29(4):291-5. PubMed ID: 11896425
[TBL] [Abstract][Full Text] [Related]
17. Reduced-intensity conditioning followed by allografting of CD34-selected stem cells and < or =10(6)/kg T cells may have an adverse effect on transplant-related mortality.
Hartwig UF; Winkelmann N; Wehler T; Kreiter S; Schneider PM; Meyer RG; Ullmann AJ; Huber C; Kolbe K; Herr W
Ann Hematol; 2005 May; 84(5):331-8. PubMed ID: 15726363
[TBL] [Abstract][Full Text] [Related]
18. The predictive value of helper T lymphocyte precursor frequencies for graft-versus-host disease and graft-versus-leukaemia effects in allogeneic bone marrow transplantation.
Russell CA; Heilmann C; Madsen HO; Vindeløv LL
Bone Marrow Transplant; 2001 May; 27(9):949-58. PubMed ID: 11436105
[TBL] [Abstract][Full Text] [Related]
19. Early (day -7) versus conventional (day -1) inception of cyclosporine-A for graft-versus-host disease prophylaxis after unrelated donor hematopoietic stem cell transplantation in children. Long-term results of an AIEOP prospective, randomized study.
Lanino E; Rondelli R; Locatelli F; Messina C; Pession A; Balduzzi A; Favre C; Santarone S; Rabusin M; Pollichieni S; Cesaro S; Dini G;
Biol Blood Marrow Transplant; 2009 Jun; 15(6):741-8. PubMed ID: 19450759
[TBL] [Abstract][Full Text] [Related]
20. Hematopoietic stem cell transplantation in children with hematological malignancies across HLA barriers--reasonable alternative?
Sedlácek P; Starý J; Vodváková S; Poloucková A; Gasová Z; Marinov I; Formánková R
Neoplasma; 2001; 48(4):302-6. PubMed ID: 11712683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
